Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients

Phase 3

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

• Registration Number: CTRI/2020/06/025998
• Lead Sponsor: ttar Pradesh University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.RT-PCR confirmed SARS-CoV-2 infected symptomatic patients admitted to the COVID-19 hospital of UPUMS

2.Patients falling in mild, moderate and severe category of COVID-19 illness

3.Patients more than 18 years of age

Exclusion Criteria

1.All critically ill patients of COVID-19

2.Patients not providing informed written consent for the study

3.Pregnant and lactating females

4.Patients of Chronic kidney disease (CKD) more than stage three

5.Asymptomatic cases

6.Study participants becoming critically ill during the course of intervention.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Micro-biologically becoming RT-PCR negative for SARS-CoV-2Timepoint: Micro-biologically RT-PCR results for SARS-CoV-2 shall be evaluated at baseline, day 6 and day 12

Secondary Outcome Measures

Name	Time	Method
1. Persistence of symptoms beyond day 5 in mild cases and day 7 in moderate cases <br/ ><br>2. Worsening of clinical features beyond day 5 except severe cases <br/ ><br>3. Changes in bio-chemical parameters like LDH, CRP, SGPT, SGOT <br/ ><br>4. Changes in haematological parameters <br/ ><br>5. Radiological worsening. <br/ ><br>Timepoint: These parameters will be evaluated on day 1, day 6 and day 12 after start of intervention.